Introduction
============

Hypertension has become the most familiar 'epidemic disease' in the world. Because of its harmful complications in the cardiovascular system, it has been identified as the mayor risk factor for high cardiac mortality. Although plenty of new anti-hypertensive medications have been developed [@b1],[@b2], ventricular hypertrophy and the subsequent congestive heart failure are still the common occurrences in most aged hypertensives [@b3]. Therefore, an effective, safe and widely used agent is urgently needed to attenuate the progress of heart failure.

The HMG-CoA-reductase inhibitors (statins) exert a protective effect on the cardiovascular system [@b4],[@b5], in addition to their lipid-lowering action [@b6]--[@b8], as indicated by the heart function restoration in the hypertensive patients with or without coronary diseases [@b9]--[@b11]. Furthermore, the JUPITER trial suggested that Rosuvastatin could effectively decrease C-reactive protein (CRP) level, thereby reducing cardiovascular event rates [@b12],[@b13]. Braunwald [@b14] doubted that this effect might be based on reducing inflammation *per se*, without an effect on LDL-C. However, the exact role and underlying mechanism of these protective effects are not completely clear.

The purpose of this study was to observe the impairment of cardiac systolic function in aged spontaneously hypertensive rats (SHRs). We reported here that Rosuvastatin could ameliorate the impairment that occurs at the end stage of hypertension in the aged SHRs; and provide evidence indicating signalling pathways are involved.

Material and methods
====================

Animals
-------

Twenty-one male SHRs, aged 52 weeks and weighing approximately 400 g, and seven age-matched normotensive male Wistar-Kyoto rats (WKY) as controls (Animal Administration Center of Fudan University, Shanghai, China) were bred ad libitum. SHRs were randomly divided into three groups, the first two receiving Rosuvastatin at a dose of 20 mg/kg/day (SHR+LD, *n* = 7) and 40 mg/kg/day (SHR+HD, *n* = 7) respectively; the third, placebo (SHR, *n* = 7) for comparison with seven WKYs as controls. Rosuvastatin and vehicle were daily administered through an intra-gastric tube for 8 weeks. All animal experimental procedures were approved by the Animal Care and Use Committee of Fudan University and performed in accordance with the guide for the care and use of laboratory animals (NIH publication no. 85-23, National Academy Press, Washington, DC, USA, revised 1996).

Measurement of systolic blood pressure
--------------------------------------

All the rats were trained to adapt themselves to the restraining cages and tail-cuff apparatus for the standard non-invasive tail-cuff method before SBP measurement [@b15], which was performed at the beginning without exception, and then every 4 weeks under their conscious conditions. Each measurement was repeated thrice.

Determination of plasma NT-proBNP concentration
-----------------------------------------------

The animals were killed so that their blood samples were collected from the abdominal aorta, the blood serum separated and NT-proBNP concentration determined by ELISA according to the manufacturer\'s instructions (R & D Systems, Minneapolis, MN, USA).

Measurement of cardiac function
-------------------------------

Trans-thoracic echocardiographic analysis was performed with an animal-specific instrument (VisualSonics® Vevo770®; VisualSonicsInc, Toronto, Canada), as previously described [@b16]. The animals were anaesthetized with isoflurane before M-mode images of the left ventricle were recorded when the heart rate was near 400 bpm. To evaluate the function of their hearts, the following parameters were measured: the left ventricular end-diastolic diameter (LVIDd), left ventricular volume (LV Volume), left ventricular ejection fraction (LVEF), left ventricular short-axis fractional shortening (LVFS), left ventricular stroke volume (SV).

Transmission electron microscopy
--------------------------------

From each group the cardiac tissues were minced into small pieces (≤1 mm^3^) and fixed in 2.5% glutaraldehyde in 0.1 mol/l sodium cacodylate buffer (pH 7.3) for 2 hrs. The specimens were rinsed in buffer, postfixed in cacodylate-buffered 2% OsO~4~, stained en bloc in uranyl acetate, dehydrated gradient in ethanol and embedded in epoxy resin. Finally, 50--70 nm super thin slices were prepared, stained with uranyl acetate and lead citrate and examined under an electron microscope (Philips TECNA10; Philips, Amsterdam, The Netherlands).

Measurement of mitochondria cytochrome *c* oxidase activity
-----------------------------------------------------------

Mitochondria were isolated from left ventricle as described previously [@b17]. The final crude mitochondrial pellet was resuspended in sucrose-histidine-EDTA buffer, and the protein concentrations were determined *via* bicinchoninic acid method. The cytochrome *c* oxidase (CCO) activity was measured as described by Subbuswamy [@b18].

Quantitative RT-PCR
-------------------

RNA was isolated and its concentrations were determined; quantitative real-time PCR analyses were performed as previously described [@b15]. The primers for BNP, SERCA2a, PLB, RyR2 type 1, RyR2 type 2, PKCα, PKCβ and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) were designed from Takara: For BNP gene, sense, 5′-CAGTCAGTCGCTTGGGCTGT -3′ and antisense, 5′-GCAGAGTCAGAAGCCGGAGT -3′. For SERCA2a gene, sense, 5′-TGAGGCCACCTCACAGCAAC-3′ and antisense, 5′-CAATGCCGTGGTCTTGGATG-3′. For PLB gene, sense, 5′-AACTAAACAGTCTGCATTGTGACGA-3′ and antisense, 5′-GCCGAGCGAGTAAGGTATTGGA-3′. For RyR2 type 1 gene, sense, 5′-GGCCATCCTTGTCCAGCATTAC-3′ and antisense, 5′- CTGCTCCGTAATGTAAAGCCCATC-3′. For RyR2 type 2 gene, sense, 5′-GAGAGCCCGGAAGCTCTGAA-3′ and antisense, 5′-GGCAACTCCATGGCACACAC-3′. For PKCα gene, sense, 5′-TCGGATCCTTACGTGAAGCTGA-3′ and antisense, 5′-AGTCGCCGGTCTTTGTCTGAA-3′. For PKCβ gene, sense, 5′- CTTGCAGAGCAAGGGCATCA-3′ and antisense, 5′-TGCCACAGAAGTCTTGGT TGTC-3′. The relative expression levels of the genes were normalized to those of GAPDH using 2^−ΔΔCt^ method.

Measurement of SERCA-2 activity
-------------------------------

The protein extraction of the cardiac tissues was prepared, as previously described [@b19]; the activity of SERCA-2 was measured according to the operating instructions of Ca^2+^-ATPase kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Western blot
------------

The ventricle tissues were removed rapidly from the rats to be stored at −80°C. The expressions of phosphorylated PKC and calcium-handling proteins were measured *via* Western blot and normalized to the protein level of β-actin or GAPDH. From the frozen ventricle tissues were extracted the total proteins, whose concentration was determined with a BCA protein assay. SERCA2a, PLB, PPI-1, NCX1 (1:1000; ABCAM, Cambridge, UK), CaMKII, RyR, PKCα, PKCβ1, PKCβ2, phospho-PKCα, phospho-PKCβ1 and phospho-PKCβ2 (1:300; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were examined by Western blot as previously described [@b15], and the optic densities were analysed using ImagePro 5.0 (Media Cybernetics, Inc., Silver Spring, MD, USA).

Statistical analysis
--------------------

The results were presented as mean ± S.E.M. and analysed using one-way [anova]{.smallcaps} followed by Fisher\'s LSD test for multiple comparisons using the SPSS software package, version 16.0 (SPSS Inc., Chicago, IL, USA), *P *\<* *0.05 considered as statistically significant.

Results
=======

Lowering effect of Rosuvastatin on blood pressure
-------------------------------------------------

The average SBP was found to be higher in SHR controls than in WKYs by 59.4% (*P *\<* *0.01). However, no significant difference was observed among SHR+LD, SHR+HD and SHR controls after 4 and 8 weeks, respectively (*P *\>* *0.05; Table[1](#tbl1){ref-type="table"}).

###### 

Changes in systolic blood pressure (SBP)

  Group    SBP (mmHg)                                                                                        
  -------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  WKY      129.14 ± 7.76                                    124.22 ± 4.49                                    128.65 ± 4.44
  SHR      205.90 ± 8.56[\*](#tf1-1){ref-type="table-fn"}   206.07 ± 6.96[\*](#tf1-1){ref-type="table-fn"}   201.80 ± 2.95[\*](#tf1-1){ref-type="table-fn"}
  SHR+LD   200.35 ± 7.04[\*](#tf1-1){ref-type="table-fn"}   203.17 ± 7.51[\*](#tf1-1){ref-type="table-fn"}   206.07 ± 4.57[\*](#tf1-1){ref-type="table-fn"}
  SHR+HD   200.31 ± 7.89[\*](#tf1-1){ref-type="table-fn"}   198.07 ± 6.69[\*](#tf1-1){ref-type="table-fn"}   202.81 ± 6.39[\*](#tf1-1){ref-type="table-fn"}

Values are mean ± S.E.M., *n* = 5, \**P* \< 0.01 *versus* WKYs.

Effect of Rosuvastatin on cardiac structure and function of SHRs
----------------------------------------------------------------

Echocardiographic measurements were conducted *in vitro* to prove whether myocardium of SHR underwent heart malfunction (Fig.[1](#fig01){ref-type="fig"}A). It was found that LVEF and LVFS were lower in SHR controls than in WKYs by 37.5% and 45.5% respectively (*P *\<* *0.05). In SHR+HD, LVEF and LVFS increased by 52.9% and 66.3%, respectively, when compared with SHR controls (*P *\<* *0.05). However, SV showed no significant difference among these four groups (*P *\>* *0.05) (Fig.[1](#fig01){ref-type="fig"}B and C).

![Echocardiographic data of %EF, %FS, SV, LVIDd and LV volume. (A) M-type echocardiographic images of WKYs, SHR controls, SHR+LD and SHR+HD. (B) Cardiac function decreased significantly in SHR controls compared with WKYs as indicated by both %EF and %FS (*P* \< 0.05); %EF and %FS were significantly enhanced in SHR+HD (*P *\<* *0.05). (C) Stroke volume with no variety in all groups. (D) and (E) Left ventricule dilated significantly in SHR controls compared with WKYs as indicated by LVIDd and LV volume (*P *\<* *0.05), but reversed in SHR+HD (*P *\<* *0.05). Values are mean ± S.E.D., *n* = 4, \**P *\<* *0.05 *versus* WKYs; \#*P *\<* *0.05 *versus* SHR controls. LVIDd: left ventricular end-diastolic diameter, LV volume: left ventricular volume, SV: left ventricular stroke volume, %EF: left ventricular ejection fraction, %FS: left ventricular short-axis fractional shortening.](jcmm0016-3052-f1){#fig01}

The results also indicated an increase in LVIDd and LV volume in SHR controls by 34.8% and 80%, respectively, when compared with WKYs (*P *\<* *0.05). In SHR+HD, significant reductions developed in LVIDd and LV volume by 20.1% and 33.9%, respectively (*P *\<* *0.05; Fig.[1](#fig01){ref-type="fig"}D and E).

According to the general changes, the results of the transmission electron microscopy showed the losses and damages of myofibrils in SHR controls when compared with WKYs (Fig.[2](#fig02){ref-type="fig"}A). Swollen, fragmented and vacuolated mitochondria were observed to be evident in SHRs, and the cristae in the mitochondria appeared distorted and in some cases were completely lysed. Furthermore, there appeared dilated and swollen sarcoplasmic reticulum in SHRs (Fig.[2](#fig02){ref-type="fig"}B). Treated with Rosuvastatin, SHRs showed improved cardiac structure as indicated by the reversed losses and damages of myofibrils, and increased volume of myofibrils. Moreover, the swollen, fragmented and vacuolated mitochondria were alleviated, whereas the sarcoplasmic reticulum was not as dilated and swollen as that of SHR controls. The improvement of the cardiac structure was more apparent in SHR+HD than in SHR+LD (Fig.[2](#fig02){ref-type="fig"}C and D).

![Ultrastructure changes. (A) Normal cardiac ultrastructure in control (WKYs). (B) Losses and damages of myofibrils in SHR controls; swollen, fragmented and vacuolated mitochondria are observed in SHR controls; dilated and swollen sarcoplasmic reticulum elements in SHR controls. (C) and (D) Volume of myofibrils increased; swollen, fragmented and distended mitochondria alleviated; dilated and swollen sarcoplasmic reticulum ameliorated in SHR+LD and SHR+HD, respectively, especially in SHR+HD. SR: sarcoplasmic reticulum; mito: mitochondria; mf: myofibril.](jcmm0016-3052-f2){#fig02}

Furthermore, compared with WKY, the CCO activity of SHR controls was decreased by 31.2% (*P \< *0.05), but increased in SHR+LD and SHR+HD by 12.8% (*P *\>* *0.05) and 36.0% (*P *\<* *0.05) respectively (Table[2](#tbl2){ref-type="table"}).

###### 

Effect of Rosuvastatin on cytochrome *c* oxidase (CCO) activity (k/min./mg of protein)

  Group          WKY           SHR                                            SHR+LD        SHR+HD
  -------------- ------------- ---------------------------------------------- ------------- ----------------------------------------------
  CCO activity   5.69 ± 1.53   3.92 ± 1.20[\*](#tf2-1){ref-type="table-fn"}   4.42 ± 1.06   5.33 ± 1.32[\#](#tf2-1){ref-type="table-fn"}

Values are mean ± S.E.M., *n* = 7, \**P* \< 0.01 *versus* WKYs; \#*P* \< 0.01 *versus* SHR controls.

In addition to the morphologic alterations, plasma NT-proBNP levels were examined to be significantly increased in SHR controls in comparison with WKYs, and to be decreased in SHR+LD and SHR+HD by 12.1% and 19.5% respectively (*P *\<* *0.01; Table[3](#tbl3){ref-type="table"}). Meanwhile, the mRNA level of BNP examined by real-time RT-qPCR showed a 5.35-fold increase in SHR controls, and a decrease in SHR+LD and SHR+HD by 47.4% and 72.3% respectively (*P *\<* *0.01; Fig.[3](#fig03){ref-type="fig"}).

![BNP (Nppb) gene expression by RT-qPCR. Real-time RT-qPCR analysis of BNP gene expression showing a significantly higher BNP expression in SHRs than WKYs (*P *\<* *0.01), but dose dependently down-regulated in SHR+LD and SHR+HD (*P *\<* *0.01). Values: mean ± S.E.M., *n* = 3, \**P *\<* *0.05 *versus* WKYs; \#*P *\<* *0.05 *versus* SHR controls; ^Δ^*P *\< 0.01 *versus* SHR+LD. BNP: B-type natriuretic peptide.](jcmm0016-3052-f3){#fig03}

###### 

Effect of Rosuvastatin on plasma NT-proBNP (ng/ml)

  Group                     WKY              SHR                                               SHR+LD                                            SHR+HD
  ------------------------- ---------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  NT-proBNP concentration   158.27 ± 13.65   209.47 ± 20.91[\*](#tf3-1){ref-type="table-fn"}   184.18 ± 17.55[\#](#tf3-1){ref-type="table-fn"}   168.62 ± 13.76[\#](#tf3-1){ref-type="table-fn"}

Values are mean ± S.E.M., *n* = 7, BNP: B-type natriuretic peptide, \**P* \< 0.01 *versus* WKYs; \#*P* \< 0.01 *versus* SHR controls.

Regulation of the mRNA and protein expressions of Ca^2+^-cycling protein in SHRs
--------------------------------------------------------------------------------

To investigate the mechanism of Rosuvastatin in the attenuated cardiac function of SHRs, the expressions of myocardium Ca^2+^-handling proteins were evaluated.

PPI-1, dephosphorylation of the PLB and thus incapable of activating SERCA2a, was significantly up-regulated by 85.9% in SHR controls (*P *\<* *0.01), and significantly down-regulated in SHR+LD and SHR+HD by 56.4% and 77.3% respectively (*P *\<* *0.01). Meanwhile, the expression of CaMKII up-regulated significantly by 40.9% in SHR+HD (*P *\<* *0.01) but not SHR+LD (*P *\>* *0.05), when compared with SHR controls (Fig.[4](#fig04){ref-type="fig"}A).

![Ca^2+^-cycling protein and mRNA expression by Western blot and Real-time RT-qPCR. (A) Protein expressions of PPI-1 are up-regulated significantly in SHR controls (*P *\<* *0.01), and reversed in SHR+LD and SHR+HD (*P *\<* *0.01); the expression of CaMKII is up-regulated significantly in SHR+HD. (B) Protein expressions of SERCA2a are significantly suppressed, whereas PLB is significantly augmented in SHR controls compared with WKYs (*P *\<* *0.05), and reversed in SHR+HD (*P *\<* *0.05). (C) mRNA expression of SERCA2a, RyR2 type 2 and RyR2 type 1 are significantly suppressed, whereas PLB is elevated in SHR controls compared with WKYs (*P *\<* *0.05); the mRNA levels of SERCA2a and RyR2 type 1 are significantly elevated in SHR+HD (*P *\<* *0.05), and the mRNA level of PLB significantly reduced in SHR+HD (*P *\<* *0.05). (D) Protein expressions of RyR2 are significantly suppressed, whereas NCX1 is significantly augmented in SHR controls compared with WKYs (*P *\<* *0.05), and reversed in SHR+LD and SHR+HD, respectively (*P *\<* *0.05). Values are mean ± S.E.M., *n* = 3, \**P *\<* *0.05 *versus* WKYs; \#*P *\<* *0.05 *versus* SHR controls; ^Δ^*P *\< 0.01 *versus* SHR+LD. PPI-1: protein phosphatase inhibitor-1; CaMKII: calcium/calmodulin-dependent protein kinase II, SERCA2a: sarcoplasmic reticulum calcium pump, PLB: phospholamban, RyR2: ryanodine receptor2, NCX1: sodium--calcium exchanger 1.](jcmm0016-3052-f4){#fig04}

The results indicated that SERCA2a, RyR2 type 1 and RyR2 type 2 mRNA were significantly decreased by 78.4%, 41.3% and 91.1%, respectively (*P *\<* *0.05), whereas PLB expressions increased 4.8-fold in SHR controls when compared with WKYs. Furthermore, the expressions of SERCA2a, RyR2 type 1 mRNA were significantly up-regulated in SHR+HD (*P *\<* *0.05), whereas those of PLB were down-regulated (*P *\<* *0.05). However, RyR2 type 2 mRNA showed no significant changes among the three groups (Fig.[4](#fig04){ref-type="fig"}C).

The expression of NCX1 was significantly up-regulated in SHR controls, but reversed in SHR+HD. Meanwhile, the protein expressions of SERCA2a, PLB and RyR2 were highly consistent with those of RT-qPCR, as indicated by Western blot (Fig.[4](#fig04){ref-type="fig"}B and D).

The SERCA2 activity was significantly decreased by 20.6% in SHR when compared with WKY (*P *\<* *0.05), but increased by 11.7% and 19.7% in SHR+LD and SHR+HD (*P *\<* *0.05) respectively (Table[4](#tbl4){ref-type="table"}).

###### 

Effect of Rosuvastatin on SERCA-2 activity \[μmol/(mg/prot/hr)\]

  Group              WKY           SHR                                            SHR+LD        SHR+HD
  ------------------ ------------- ---------------------------------------------- ------------- ----------------------------------------------
  SERCA-2 activity   5.38 ± 0.46   4.27 ± 0.35[\*](#tf4-1){ref-type="table-fn"}   4.77 ± 0.58   5.11 ± 0.37[\#](#tf4-1){ref-type="table-fn"}

Values are mean ± S.E.M., *n* = 7, SERCA2a: sarcoplasmic reticulum calcium pump, \**P *\<* *0.01 *versus* WKYs; \#*P* \<* *0.01 *versus* SHR controls.

Decreased expressions and phosphorylation of PKCα and PKCβ2 in SHRs
-------------------------------------------------------------------

PKC signalling pathway has been identified as a given pathway in the Ca^2+^-regulating process. It was found that Rosuvastatin down-regulated significantly the mRNA expression of PKCα and PKCβ by 64.5% and 67.7% in SHR+LD, respectively, and by 7.29% and 66.4% in SHR+HD respectively (*P *\<* *0.01). Furthermore, the ratios of phosphorylation to the total PKCα and PKCβ2 were significantly inhibited, but it was not true of PKCβ1 in SHR+LD and SHR+HD when compared with SHR controls (Fig.[5](#fig05){ref-type="fig"}).

![mRNA and protein expression of PKCα and PKCβ by real-time RT-qPCR and Western blot. (A) Expressions of total PKCα and PKCβ2 are significantly down-regulated in SHR+LD (*P *\<* *0.05), but not the same with the expression of total PKCβ1 (*P *\>* *0.05). (B) Expressions of phospho-PKCα and phospho-PKCβ2 are significantly down-regulated in SHR+LD and SHR+HD (*P *\<* *0.05), but no significant changes are found in the expression of phospho-PKCβ1 (*P *\>* *0.05). (C) Ratio of phosphor PKCα to total PKCα and the ratio of phosphor PKCβ2 to total PKCβ2 are down-regulated significantly in SHR+LD and SHR+HD (*P *\<* *0.01). (D) mRNA level of the whole PKCα (*P *\<* *0.05) and PKCβ (*P *\>* *0.05) gene expressions is down-regulated in SHR controls and lowered considerably (*P *\<* *0.05) in SHR+LD and SHR+HD. Values are mean ± S.E.M., *n* = 3, \**P *\<* *0.05 *versus* WKYs; \#*P *\<* *0.05 *versus* SHR controls; ^Δ^*P *\< 0.01 *versus* SHR+LD. p-PKCα: phosphorylation of protein kinase Cα;p-PKCβ1: phosphorylation of protein kinase Cβ1;p-PKCβ2: phosphorylation of protein kinase Cβ2.](jcmm0016-3052-f5){#fig05}

Discussion
==========

Most of the hypertensives tend to develop cardiac hypertrophy and even heart failure, although they receive the administration of anti-hypertensive medications. Rosuvastatin has been reported to be controversial in attenuating cardiac function [@b9], improving survival rate in those with diastolic heart failure [@b10] and decreasing all-cause mortality following a diagnosis of heart failure [@b11]. However, the mechanisms of these protective effects remain unknown.

In the present study, we used 52-week-old SHR as the model of the end-stage hypertensive heart disease, finding that the aged SHRs developed systolic heart failure characterized by the abnormal parameters of echocardiography and the increased NT-proBNP. We also found that the mitochondria were swollen, fragmented and vacuolated and the sarcoplasmic reticulum (SR) were dilated and swollen in SHRs. The mitochondria CCO and SERCA2 activity were down-regulated. In addition, the decreased expressions of SERCA2a, RyR2 and CaMKII were accompanied by an increase in PLB, NCX1 and PPI-1, suggesting a possible mechanism that the failure of SR can induce the impairments of Ca^2+^-handling proteins, thus causing heart failure.

Rosuvastatin treatment can ameliorate heart failure of aged SHRs independent of blood pressure lowering, *via* dephosphorylation of PKCα/β2, followed by dephosphorylation of PPI-1 and increased expression of CaMKII, thus promoting phosphorylation of PLB and up-regulating SERCA2 activity.

It is well recognized that high blood pressure increases ventricular wall tension, stimulates cardiomyocytes to express cytokines [@b20], causes ventricular remodelling and consequently develops heart failure, the pathological changes of which can be attenuated with a reduction in SBP, thereby improving cardiac function. Statins have been reported on lowering blood pressure in both SHR and WKY/L-NAME rats by reducing total peripheral vascular resistance [@b21]. However, there have been controversies on their anti-hypertensive effects. Loch and Saka reported that statin treatment failed to alter blood pressure in Dahl salt-sensitive rats [@b22],[@b23].

In the present study, no significant changes in SBP were observed among the three SHR groups. The main reason responsible for this could be that 52-week-old SHRs had developed severe endothelial compromise, perivascular fibrosis and arterial stiffness. In this case, Rosuvastatin with weak anti-hypertensive effect could not alter significantly the peripheral resistance and the resultant SBP. This result was consistent with the report by Prandin MG that the confounding factors, such as age and baseline SBP, might influence the blood pressure of each individual [@b24].

Previous studies have shown that statins can ameliorate BNP up-regulation [@b25] and restore heart function in hypertensives [@b9] in addition to their lipid-lowering effects. This is also the case for the results from this study that a high concentration of Rosuvastatin could reverse the expressions of SERCA-2a, RyR2, PLB, NCX1, PPI-1 and CaMKII, thus ameliorating the cardiac malfunction at the end stage of hypertension.

However, there have been controversies around the therapeutic effect of statins on cardiac malfunction. In John Kjekshus' trial, even Rosuvastatin could reduce the total number of hospitalizations for heart failure, but produce no effect on heart failure mortality [@b26]. The UNIVERSE trials also failed to demonstrate a therapeutic effect of statin on LV remodelling in the patients with chronic heart failure [@b27]. It could be that those enrolled had been well treated for heart failure with a standard therapy before Rosuvastatin, which reduced significantly the population with potentially fatal heart failure enrolled in the trial. This could also be because the patients with the heart failure of ischaemic or non-ischaemic aetiology were not differentially enrolled. Thus, the different inclusion and exclusion criteria could cause different pathophysiological and aetiological changes in heart failure, confusing the consistence of the results in the cohort.

The previous literature has shown that PKCα/β function as fundamental regulators of cardiac contractility and Ca^2+^-handling proteins in cardiomyocyte [@b28]--[@b31], and PKCβ2 inhibition attenuates myocardial infarction and hypertension-induced heart failure [@b32],[@b33]. Moreover, the enhancement in cardiac contractility associated with PKCα gene deletion protected the myocardium against pressure overload-induced heart failure and dilated cardiomyopathy [@b34].

Our previous study [@b15] indicated that Rosuvastatin could decrease the expression of angiotensin II type 1 receptor (AT~1~R), one type of G-protein coupling receptor, in the ventricle, and resultantly inhibit mitogen-activated protein kinase (MAPK) signal pathway, thus ameliorate cardiac hypertrophy in hypertensive heart disease. To investigate whether PKC is involved in the inhibitory effect of AT~1~R by Rosuvastatin, we examined the mRNA and protein expression of PKCα/β in the myocardium, and found down-regulation of PKCα/β as well as decreased ratios of phosphorylation to total PKCα and PKCβ2 after Rosuvastatin treatment. On the basis of the data presented, we concluded that Rosuvastatin could decrease the expression of AT~1~R, and consequently suppress the activation of Gα subunit [@b35]--[@b37], restrain G-protein coupling signal pathway, thus inhibit the phosphorylation of PKCα/β2 and ameliorate the impairment of calcium-handling proteins.

It was reported that the decreased expression of PKC resulted in inactivation of PPI-1, activating the phosphorylation of protein phosphatase-1, which in turn regulated PLB phosphorylation [@b38],[@b39], thereby promoting the function of SERCA-2a responsible for Ca^2+^ loading and the magnitude of the Ca^2+^ transients [@b40],[@b41]. In this study, therefore, a decrease in SERCA2a expression along with an increase in PLB and NCX1 protein level in SHRs could lead to a decreased SR function causing a decreased SR Ca^2+^ store and rate of Ca^2+^ releasing from the SR. These changes were found to be capable of affecting the contractile function of the heart, which were reversed following the administration of Rosuvastatin, suggesting that Rosuvastatin could ameliorate the changes in Ca^2+^-handling protein *via* PKC signalling pathway.

It can be concluded from this study that Rosuvastatin therapy was proved to exert a protective effect on the end stage of hypertension with dephosphorylation of PKCα/β2, causing the consequent dephosphorylation of PPI-1 and increased expression of CaMKII, which could result in the decreased expression of PLB and increased SERCA2a, RyR2 in the aged SHRs.

Beyond lipid lowering, statins have many pleiotropic effects, such as stimulating stem cells [@b42],[@b43], activating immune system [@b44], activating heme oxygenase-1 at the stress response elements [@b45] and having synergistic effects with telmisartan on endothelial progenitor cells [@b46]. Those we discovered above can be one of the statins' pleiotropic effects, which can make statins potentially beneficial to patients with heart failure, for whom hypertension is the main risk factor.
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